Conference Description
Key Takeaways
- Focuses on artificial intelligence, machine learning and data science applications across the pharmaceutical lifecycle
- Addresses real-world data governance, FAIR data principles and regulatory compliance for digital therapeutics
- Explores emerging technologies including quantum computing, blockchain platforms and multi-omics integration
- Designed for pharmaceutical executives, clinical researchers, data scientists, regulatory professionals and digital health innovators
- Examines the convergence of digital therapeutics with traditional pharmaceutical development
Introduction
The Digi-Tech Pharma & AI 2027 Conference brings together pharmaceutical executives, technology specialists, regulatory authorities and healthcare innovators to examine how digital transformation is reshaping drug discovery, clinical development and patient care. As the industry grapples with mounting pressure to accelerate development timelines while meeting increasingly complex regulatory requirements, the integration of artificial intelligence, real-world data and advanced analytics has moved from experimental to essential. This event addresses the technical, operational and governance challenges that organisations face when implementing these technologies at scale.
About This Event
The conference serves as a platform for knowledge exchange between pharmaceutical companies, biotechnology firms, technology providers and regulatory bodies. Programming spans the complete pharmaceutical lifecycle, from early-stage target identification through to post-market surveillance and real-world evidence generation. The event emphasises practical implementation, with discussions centred on operational challenges, compliance frameworks and measurable outcomes rather than theoretical possibilities.
Artificial Intelligence and Machine Learning in Drug Development
A substantial portion of the programme examines how AI and machine learning are being deployed across pharmaceutical research and development. Sessions address the application of algorithms and predictive models to lead compound design, target identification and validation processes. The conference also explores how these technologies support clinical data interpretation, enabling researchers to extract meaningful insights from increasingly complex datasets.
The relationship between AI capabilities and big data infrastructure receives particular attention. As pharmaceutical organisations accumulate vast quantities of genomic, proteomic and clinical information, the ability to integrate and analyse multi-omics data has become a competitive differentiator. Discussions cover the technical architectures and analytical approaches required to translate this data into actionable drug discovery insights.
Real-World Data and Evidence Generation
The growing importance of real-world data in regulatory decision-making and clinical research forms another central theme. Sessions examine how RWD and real-world evidence are being used to supplement traditional clinical trial findings, inform regulatory submissions and support post-market safety monitoring. Best practices in data governance receive dedicated coverage, reflecting industry recognition that data quality and provenance are fundamental to regulatory acceptance.
The conference addresses the practical challenges of implementing FAIR data principles—findability, accessibility, interoperability and reusability—within pharmaceutical R&D environments. These principles have gained traction as organisations seek to maximise the value of their data assets while facilitating collaboration across research networks.
Regulatory Compliance and Data Governance
As digital technologies become embedded in pharmaceutical operations, regulatory frameworks continue to evolve. The programme examines current approaches to AI and machine learning regulatory compliance, including the documentation and validation requirements that organisations must satisfy. Sessions also address data privacy, integrity and cybersecurity considerations specific to digital R&D environments, alongside GxP compliance requirements for digital audit trails.
Ethical considerations in AI-driven drug discovery receive dedicated attention, reflecting broader industry and regulatory focus on transparency, explainability and responsible innovation. Trust and governance frameworks for digital transformation initiatives are explored as essential foundations for sustainable adoption.
Emerging Technologies and Digital Health Integration
Beyond established AI applications, the conference explores emerging technologies with potential to reshape pharmaceutical operations. Quantum computing applications in advanced drug discovery represent one frontier, while blockchain and AI-based platforms for drug development address supply chain integrity and data provenance challenges. The adoption of IoT technologies and cloud computing infrastructure within pharmaceutical settings also features in the programme.
The convergence of digital therapeutics with traditional pharmaceutical development reflects a broader shift toward patient-centric approaches. Sessions examine how virtual and hybrid clinical trial models, remote monitoring technologies and digital health strategies can improve patient engagement while generating richer clinical evidence.
Who Should Attend
The conference is designed for senior professionals across pharmaceutical, biotechnology and health technology organisations. This includes executives and specialists in clinical research, drug discovery, translational informatics, bioinformatics, regulatory affairs, pharmacovigilance and quality compliance. Data science, AI and analytics professionals will find relevant technical content, as will those responsible for digital transformation, IT infrastructure and cybersecurity. The event also serves contract research organisations, technology solution providers and investors focused on the pharmaceutical technology sector.